ICML 2019: Improved Outcomes With Brentuximab Vedotin in Cutaneous Lymphoma
Posted: Tuesday, July 2, 2019
According to research presented at the 2019 International Conference on Malignant Lymphoma (ICML) in Switzerland (Abstract 232), patients with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL) receiving brentuximab vedotin experienced improved objective response rates lasting at least 4 months (ORR4) and progression-free survival compared with those receiving a physician’s choice treatment of either methotrexate or bexarotene. The final results of the ALCANZA study confirmed the trial’s initial findings.
“[Brentuximab vedotin] demonstrated extended [time to next therapy versus] physician’s choice, suggesting that durable [brentuximab vedotin] responses were clinically meaningful,” concluded S.M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, and colleagues.
The ALCANZA trial included 128 patients with CD30+ CTCL who were randomly assigned to receive either brentuximab vedotin (n = 64) or physician’s choice (n = 64). Brentuximab vedotin was found to be more effective than physician’s choice, achieving a 59.4% ORR4 versus 7.8% according to researchers (P < .001). An independent review found brentuximab vedotin to be associated with a 54.5% ORR4 versus 12.5% (P < .001). Brentuximab vedotin also resulted in superior median progression-free survival (16.7 months vs. 3.5 months) and time to next therapy (14.2 months vs. 5.6 months). The probability of patients in the brentuximab group not requiring subsequent antineoplastic therapy was 65.5% at 1 year and 23.6% at 2 years.
As expected, peripheral neuropathy occurred in 67% of patients receiving brentuximab vedotin. Of these events, 18 were grade 1, 20 were grade 2, and 6 were grade 3. At the final analysis, 86% of patients treated with brentuximab vedotin who had peripheral neuropathy achieved complete resolution or improvement by at least one grade, compared with 82% at the initial analysis. A total of 23 deaths and 25 deaths occurred in the brentuximab vedotin and physician’s choice groups, respectively.
Disclosure: The study authors’ disclosure information can be found at lymphcon.ch.
